Journals / Türk Toraks Dergisi / 2009 / Cilt: 10 - Sayı: 2

Time to clinical stability and symptom resolution in patients with community acquired pneumonia and their relationships to serum CRP levels

Toplum kökenli pnömoni hastalarında klinik stabilite zamanı, semptom rezolüsyonu ve serum C-reaktif protein ilişkisi

Pages
47–55
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The baseline PSS and CRP levels are not useful in predicting TCS, and the lack of CRP response on consecutive measurements is an independent factor affecting extension of the TCS in CAP patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, the role of consecutive measurements of pneumonia symptom scores (PSS) and serum C-reactive protein (CRP) levels in predicting the time to clinical stability (TCS) of patients with community-acquired pneumonia (CAP) were investigated.
📊
Key Findings & Data:Serum CRP levels and PSS were measured on admission and at the 3rd and 10th days of admission.
💡
Conclusion & Impact:Conclusion: The baseline PSS and CRP levels are not useful in predicting TCS, and the lack of CRP response on consecutive measurements is an independent factor affecting extension of the TCS in CAP patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Pnömoni · C-reaktif protein · Anketler

Abstract

Introduction: In this study, the role of consecutive measurements of pneumonia symptom scores (PSS) and serum C-reactive protein (CRP) levels in predicting the time to clinical stability (TCS) of patients with community-acquired pneumonia (CAP) were investigated. Material and Method: The hospitalized CAP patients were grouped according to CAP guidelines of the Turkish Thoracic Society (TTS). The clinical visits were made every day in order to define the TCS. Serum CRP levels and PSS were measured on admission and at the 3rd and 10th days of admission. Results: Seventy seven patients with CAP (mean age 41.7 ± 24; 64 M/13F) were included in this study. According to TTS guidelines, patients were grouped as Group I-II (n=21), Group IIIA (n=26), Group IIIB (n=19) and Group IV (n=11). For the whole population, the mean TCS was 4±2.1 days. In patients with sepsis or whose antibiotic treatment had failed, a longer TCS was found by univariate analysis. The mean PSS measured on all days and serum CRP levels measured on the 3rd day of treatment were higher in patients with a TCS > 3 days (n=33) than those with a TCS ≤ 3 days (n=41) (p=0.045, p=0.005, p=0.001 and p=0.0001, respectively). The lack of CRP response at day 3 was found as a significant independent factor causing extension of TCS (OR: 3.32; 95% CI: 1.16-9.50; p=0.025). Conclusion: The baseline PSS and CRP levels are not useful in predicting TCS, and the lack of CRP response on consecutive measurements is an independent factor affecting extension of the TCS in CAP patients.

Özet

Giriş: Bu çalışmada toplum kökenli pnömoni (TKP) hastalarında klinik stabilite zamanının (KSZ) belirlenmesinde ardışık ölçülen pnömoni semptom skoru (PSS) ve serum C-reaktif protein (CRP) düzeylerinin rolü araştırılmıştır. Gereç ve Yöntem: Hastaneye yatırılan TKP hastaları Türk Toraks Derneği (TTD) TKP rehberine göre gruplandırıldı. KSZ, yapılan günlük vizitlerle belirlendi. Yatış günü, 3. ve 10. günde hastaların PSS ve serum CRP düzeyleri ölçüldü. Bulgular: Çalışmaya 77 TKP hastası (ortalama yaş: 41.7 ± 24; 64 E/ 13 K), dahil edildi. TTD'ye göre hastalar, 21'i Grup I-II, 26'sı Grup IIIA, 19'u Grup IIIB ve 11'i Grup IV olarak gruplandı. Tüm hastalarda ortalama KSZ 4±2.1 gün olarak bulundu. Sepsisli ve antibiyotik tedavisine yanıtsız olgularda KSZ daha uzun bulundu. KSZ > 3 gün olan grupta, (n=33) her üç gündeki ortalama PSS ve 3. gün CRP düzeyi, KSZ ≤ 3 gün olan gruba (n=41) göre daha yüksekti (sırasıyla, p=0.045, p=0.005, p=0.001 ve p=0.0001). Üçüncü günde CRP yanıtının olmaması, KSZ'nin uzamasını artıran bağımsız bir risk faktörü olarak bulundu (OR: 3.32; % 95 GA: 1.16-9.50; p=0.025). Sonuç: TKP hastalarında bazal PSS veya CRP düzeylerinin KSZ'nin tahmin edilmesinde faydalı yöntemler olmadığı; ardışık CRP düzeylerinde yanıt alınamamasının ise KSZ'nin uzamasına etkili, bağımsız bir faktör olduğu bulunmuştur.

🔖

Cite This Article

BİRCAN, A., YILMAZER, İ., GÖKIRMAK, M., SONGÜR, N., ÖZTÜRK, Ö., ŞAHİN, Ü., AKKAYA, A. (2009). Time to clinical stability and symptom resolution in patients with community acquired pneumonia and their relationships to serum CRP levels. Türk Toraks Dergisi, Cilt: 10 - Sayı: 2, 47–55. https://ajindex.com/articles/329676

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50
  2. Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-8
  3. Menendez R, Torres A, Zalacain R, et al. Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5
  4. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-60
  5. Toraks Derneği. [Erişkinlerde Toplum Kökenli Pnömoni Tanı ve Tedavi Rehberi.] Toraks Dergisi 2002;3:1-15
  6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:27-72
  7. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56:iv1 iv64
  8. Arnold F, LaJoie A, Marrie T, et al. Community Acquired Pneumonia Organisation. The pneumonia severity index predicts time to clinical stability in patients with communityacquired pneumonia. Int J Tuberc Lung Dis 2006;10:739-43
  9. Menendez R, Torres A, Rodríguez de Castro F, et al. Neumofail Group. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-90
  10. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia. Implications for practice guidelines. JAMA 1998;279:1452-7
  11. Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community acquired pneumonia? J Gen Intern Med 2001;16:599-605
  12. Metlay JP, Atlas SJ, Borowsky LH, Singer DH. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998;92:1137-42
  13. Marrie TJ, Beecroft MD, Hermna-Gnjidic Zeljka. Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis. J Infect 2004;49:302-9